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Intellectual disabilityMicrodeletions of 17q12 including the hepatocyte nuclear factor 1 beta (HNF1B) gene, aswell as point mutations
of this gene, are associated with the Renal Cysts and Diabetes syndrome (RCAD, OMIM 137920) and genitouri-
nary alterations. Also, microdeletions encompassing HNF1B were identiﬁed as a cause of Mayer–Rokitansky–
Küster–Hauser Syndrome (MRKH, OMIM277000) in females and, recently, were associatedwith intellectual dis-
ability, autistic features, cerebral anomaly and facial dysmorphisms.
In this report, we describe a boy with a deletion in 17q12 region detected by SNP array, encompassing theHNF1B
gene, that showed dysmorphic features, intellectual disability (ID), serious speech delay and autistic features. In
addition, obesity was observed. In order to study the parental origin of the rearrangement, we analyzed selected
SNPs in the deleted area in the patient and his parents, showing Mendelian incompatibilities suggesting a de
novo deletion on the chromosome of maternal origin.
Our case conﬁrms the incomplete penetrance and variable expressivity of this deletion, its complex clinical var-
iability, and strengthens the evidence that ID and stereotyped behaviorsmay be part of the phenotypic spectrum
characterizing the affected patients. Also, it is useful to further delineate the phenotypes associated to the dele-
tion being the ﬁrst case in which obesity has been documented. We present a genotype–phenotype correlation
discussing the possible role of some genes, encompassed by the deletion, in the etiology of the observed
phenotypes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Recurrent genomic rearrangements of chromosome 17q12 are asso-
ciated with varied clinical phenotypes. In particular, microdeletions
encompassing the hepatocyte nuclear factor 1beta gene (HNF1B,
OMIM 189907) are considered the cause of Renal Cysts and Diabetespha; ADHD, Attention Deﬁcit
CNTNAP2, Contactin associated
eoxyribonucleic Acid; FOXP2,
tor 1 Beta; ID, Intellectual
eobox 1 LIM homeobox 1;
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a).
ights reserved.(RCAD) syndrome, an autosomal dominant disorder (Bingham et al.,
2004). This condition results in a clinically distinguishable phenotype,
whosemajor features include cystic renal disease, renal anomaly, matu-
rity onset diabetes of the young type 5 (MODY5), pancreatic atrophy,
and liver abnormalities (Bellanné-Chantelot, 2005; Nagamani et al.,
2010).
Also, deletions in 17q12 have recently been identiﬁed as a rare cause
of Mayer–Rokitansky–Küster–Hauser Syndrome (MRKH). This syndrome
is deﬁned in 46,XXwomen by congenital absence of the uterus and upper
part of the vaginawith otherwise normal sexual development and can be
associated with renal, skeletal and/or hearing defects (Bernardini et al.,
2009; Nik-Zainal et al., 2011 The 17q12microdeletions are not character-
ized by intellectual disability or other neurobehavioral phenotypes, while
it was observed that the duplication of the same region causes intellectual
disability, autism spectrum disorder and speech delay (Brandt et al.,
2012). Although earlier reports of cases with the 17q12 microdeletion
syndromedid not include cognitive impairment as a part of the character-
istic phenotype of these deletions (Mefford et al., 2007), recently, some
authors (Dixit et al., 2012; Loirat et al., 2010; Mukamel et al., 2011)
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out autism, suggesting that cognitive impairment and a behavioral phe-
notype could be part of the clinical features conveyed by the 17q12
microdeletion. In order to deeply investigate the phenotype associated
with 17q12 microdeletion, we describe the clinical and molecular data
of a patient carrier of a de novo deletion in the 17q12 region, 1.42 Mb in
size,withdysmorphic features, serious speechdelay, intellectual disability
(ID), stereotyped behaviors and obesity, but without the typical clinical
features usually present in patients harboring this deletion. Finally, we
discuss candidate genes for the observed traits and, in particular, we dis-
cuss the possible role of involvement ofMIR2929 in the del17q12 neuro-
logical phenotype observed in our patient.
2. Clinical description
The patient is a 12-year-old boy whose parents are non-
consanguineous. There is no family history of ID, autism, or other psy-
chiatric illness. He was born at 41 weeks of gestation by cesarean sec-
tion. The child had been naturally conceived and the parents were not
aware of any abnormalities on prenatal ultrasounds. At birth an echo-
cardiographic exam was performed, which showed transposition of
great arteries, surgically treated at 40 days of life.
Developmentalmilestones were normal until 14 months. In the lan-
guage domain, the ﬁrst use of single words by the patient occurred at
5 years without further maturation of verbal communication skills,
and currently he has a vocabulary of a few words.
At a physical examination at the age of 11 years, his weight was
62 kg (N97th centile), his height was 152 cm (N75th centile), and his
head circumference measured 52 cm (b10th centile). He was engaging
in repetitive and compulsive-like behaviors. The patient showed atten-
tion deﬁcit hyperactivity disorder (ADHD) and intellectual disability.
He expressed himself in language characterized by vocalizations
with communicative value and he was even able to answer simple de-
liveries. The patient kept the static standing with plantigrade support
and with evident motor clumsiness during the gait pattern. The manip-
ulative skills were characterized by digitopalmar prehension with
greater intentionality to the right and lack of integration into ﬁne
motor activities. Neurological exams showed normal cranial nerves,
normal muscle tone and trophism, normal ROT symmetrical in all four
limbs and no evidence of stenic deﬁcits or pyramidal signs.
On physical examination the patient showed dysmorphic features in
the form of right posterior plagiocephaly, facial asymmetry, narrow
forehead, hypotelorism, wide and ﬂeshy auricular pavilions, protruding
cheekbones, long philtrum, thin upper lip, tuft of hair on the neck to the
left parotid region, clinodactyly of the ﬁfth ﬁngers of the hands (Supple-
mentary Fig. 1).
A full ultrasound abdomen exam showed regular liver morfovolu-
metry and echotexture, normal gallbladder, not dilated intra-and extra-
hepatic bile ducts, portal vein caliber regular hilum, regular spleen
echotexture and morphovolumetry. Kidney's echotexture and
morfovolumetry were regular and without signs of hydronephrosis,
bladder was free of endoluminal alterations.
3. Matherials and methods
3.1. Snp array assay
Blood was obtained from the proband and his parents after signed
informed consent. The studywas designed to perform parental and pro-
band samples concurrently on three individual chips. GenomicDNAwas
isolated from peripheral blood lymphocytes of the patient and the par-
ents by using BioRobot EZ1 (Quiagen, Solna, Sweden). DNA concentra-
tion and purity were determined with a ND-1000 Spectrophotometer
(NanoDrop Technologies, Berlin, Germany) while SNP-array analysis
was performed by using Affymetrix GeneChip Genome Wide Human
SNP 6.0 Array (Affymetrix, Santa Clara, CA). This array has, on average,an inter-marker distance of 700 bp and makes possible an excellent as-
sessment of possible breakpoints of deletions to assess copy gains or
losses. The SNP 6.0 assay was performed according to the
manufacturer's protocol, starting with 500 ng of DNA. Brieﬂy: total ge-
nomic DNA was digested with restriction enzymes (NspI and StyI), li-
gated to appropriate adapters for the enzymes, and subjected to PCR
ampliﬁcation using a single primer. After digestion with DNase I, the
PCR products were labeled with a biotinylated nucleotide analog using
terminal deoxynucleotidyl transferase and hybridized to the microar-
ray. Hybridization was carried out in the Affymetrix Hybridization
Owen 450 while subsequent washing and staining steps were per-
formed using the Fluidic Station 450 and ﬁnally the array was scanned
with the GeneChip Scanner 3000 7G using Command Console Software
(Affymetrix, Santa Clara, CA, USA).
Analysis was performed using Genotyping Console Software 4.1
(Affymetrix, Santa Clara, CA, USA) and Birdseed v2-algorithm. Sam-
ples were normalized against 270 International HapMap samples
(Affymetrix, CA) while an additional 80 in-house control samples,
which were hybridized in our facility, were used to decrease technical
variation. For the copy number analysis, we used regional GC correction
and required 25markers to be foundwithin the changed region and the
size of the region to be at least 200 kb. The ampliﬁed and/or deleted
regions were detected using a standard Hidden Markov Model
(HMM) method. Genotyping Console Browser (Affymetrix, CA) was
used to illustrate changes detected while the University of California
Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu/cgi-bin/
hgGateway), assembly GRCh37, was used to map the genomic coordi-
nates and ﬁnd the genes within the copy number altered region.
3.2. Haplotype analysis
A total of 23 informative single nucleotide polymorphisms (SNPs)
were selected from 1827 SNPs located at 17q12 (physical position
31.8–38.1 Mb) for haplotype structural analysis. Phased haplotypes
were inferred from genotype data in both parents and child. The 17
SNPs (from rs9912731, physical position 35,239,742 bp, to rs8069122,
physical position 36,211,659 bp) showed inconsistencies of Mendelian
inheritance, marking hemizygous genotypes of these SNPs being
miscalled as homozygous.
3.3. Mutational analysis
To amplify the entire coding sequence andﬂanking intronic portions
of LHX1, 5 primer pairs were designed.Mutational analysis of LHX1 gene
has been performed as already reported in Bernardini et al. (Bernardini
et al., 2009).
To amplify the entire coding sequence andﬂanking intronic portions
of ACACA, 53 primer pairs were designed (Supplementary Table 1). The
PCR reactions (except exon 45) were performed in a 25 μL volume con-
taining 1.5 mMMgCl2, 250 μMdNTPs, 1 μMof each primer, 50 ng of ge-
nomic DNA and 1.5 U of AmpliTaq Gold DNA polymerase (Applied
Biosystems, Foster City, CA) with an initial denaturation step of
12 min at 95 °C followed by 35 cycles at 94 °C, 30 s; 60 °C, 30 s; 72 °C,
30 s and a ﬁnal elongation of 7 min at 72 °C. Exons 27, 34–35 were am-
pliﬁed with an initial denaturation step of 12 min at 95 °C followed by
35 cycles at 94 °C, 30 s; 58 °C, 30 s; 72 °C, 30 s and a ﬁnal elongation
of 7 min at 72 °C. ACACA exon 45 has been ampliﬁed in a 25 μl volume
containing 5 μL of 5× GC-Rich solution (Roche Applied Science, Mann-
heim, Germany), a 2.5 μL of 10× FastStart Taq DNA Plymerase Buffer
(Roche Applied Science, Mannheim, Germany), 250 μM dNTPs, 1 μM
of each primer, 50 ng of genomic DNA and 2 U of FastStart Taq DNA
Plymerase (RocheApplied Science,Mannheim, Germany)with an initial
denaturation step of 3 min at 95 °C followed by 35 cycles at 94 °C, 30 s;
58 °C, 30 s; 72 °C, 30 s and a ﬁnal elongation of 7 min at 72 °C. All PCR
products were puriﬁed using ExoSAPIT (USB Corporation, Cleveland,
OH) and sequenced directly on an automated sequencer (ABI 3100;
Fig. 1. (A) GenomeWide Human SNP 6.0 Array results of themother, father and proband. A 17q12 loss of 1.428Mb in the probandwas observed. (B) A screenshot from the UCSC genome
browser showing the deleted region at cytogenetic location 17q12, from 34,816,256 to 36,244,358 bp, based on the Human Genome February 2009 (GRCh37/hg19) assembly.
375P. Palumbo et al. / Gene 538 (2014) 373–378Applied Biosystems, Foster City, CA) using the ABI-PRISM big-dye Ter-
minator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Fos-
ter City, CA).
4. Results
SNP-array analysis of the proband revealed a heterozygous deletion
involving interstitial chromosome 17q12, from SNP_A-8624766
(34,816,256 bp) to SNP_A-1828153 (36,244,358 bp; rs1963088)
(USCS Genome Browser build February 2009 hg19), which were the
ﬁrst and the last deleted oligonucleotide from the centromere respec-
tively. The ﬂanking normal probes were CN_754222 (34,629,684 bp)
and CN_763010 (36,282,179 bp). The subsequent microarray analysis
of the proband's parents using the same platform revealed normal chro-
mosomes 17 in both of them, indicating a de novo deletion in the child
(Fig. 1A). The minimum size of loss was 1.428 Mb, covered by 973 SNP
array probes, while the maximum size of deletion was 1.652 Mb. The
molecular karyotype of the patient was arr17q12 (31,500,383x2,
34,816,255-36,244,358x1, 36,300,595x2)dn. The hemizygous region in-
cluded the entire coding sequence of 16 genes (CCL4L2, TBC1D3H,TBC1D3G, ZNHIT3, MYO19, PIGW, GGNBP2, DHRS11, MRM, LHX1, AATF,
ACACA, TADA2A, DUSP14, SYNRG, HNF1B) and a miRNA (mir-2909)
(Fig. 1B). The subsequent genotype analysis showed that the deletion
affects the maternal allele (Fig. 2). The deletion in the patient, as well
as the parental origin, were conﬁrmed by a second experiment using
the CytoScan HD array (Affymetrix, Santa Clara, CA) which contains
more than 2.6 million markers for copy number analysis and approxi-
mately 750,000 SNPs that fully genotype with greater than 99% accura-
cy. A loss of 1.421 Mb was identiﬁed at 17q12, covered by 1652
SNP array probes (Supplementary Fig. 2). The proximal breakpoint
(centromeric) was located between the last present probe S-4ESPG
(34,477,480 bp; rs916841) and the ﬁrst deleted probe C-6IWKL
(34,822,466 bp), while the distal breakpoint (telomeric) was located
between the last deleted probe S-4AOXU (36,244,358 bp; rs1963088)
and the ﬁrst present probe C-3ZZGO (36,283,612 bp). The telomeric
end point of the deletion identiﬁed is the same in both the analysis
while the centromeric end point is quite different due to the slightly dif-
ferent distribution of the probes on the two arrays. It is important to
note that this difference in size does not modify the gene content of
the reported deletion.
Fig. 2. Results of haplotype analysis. The phased haplotypes based upon 23 selected infor-
mative SNPs from the centromeric, the deleted and the telomeric regions are reported.
Hemizygous calls instead of homozygous calls of SNPs within the deleted region are
shown since loss of one copy in the proband is conﬁrmed. The marked markers are infor-
mative SNPs to demonstrate maternal deletion event of the region.
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were found in LHX1 gene, while in ACACA genewe ﬁnd a polymorphism
in exon 50 (T2063T).
5. Discussion
The 17q12 deletion, involving HNFB1 gene, is associated with the
RCAD (renal cysts and diabetes) syndrome, characterized by cystic
renal disease, renal anomaly, MODY5, pancreatic atrophy and liver ab-
normalities. In some cases the same deletion is associated with MRHK
(Mayer–Rokitansky–Küster–Hauser) syndrome, characterized by con-
genital absence of the uterus and upper part of vagina with otherwise
normal sexual development in 46,XX women and can be associated
with renal, skeletal and/or hearing defects. The 17q12 deletion was
the ﬁrst genomic disorder resulting in diabetes and was the third geno-
mic disorder with signiﬁcant renal involvement (Mefford et al., 2007).
Chen et al. (2010)) reviewed several cases of HNF1B anomalies (espe-
cially mutations) in renal cysts and diabetes syndrome/maturity onset
diabetes of the young type 5, deducting that renal structure anomalies
(RSA) represented themost frequent phenotype (89.6%)while diabetes
mellitus (DM) was 45%.The majority of 17q12 deletion cases are intellectually normal. De-
spite it was observed that the duplication of the same region causes in-
tellectual disability, autism spectrumdisorder and speech delay (Brandt
et al., 2012), ﬁrst reports of 17q12 microdeletions did not associate the
rearrangement with any form of intellectual disability and/or autism,
suggested that there may also be a correlation between 17q12
microdeletions and intellectual disabilities/autism, but these features
do not seem to be completely penetrant. Moreno-De Luca and SGENE
Consortium (2010) demonstrated that 17q12 deletion, in addition to
causing kidney disease, is a recurrent pathogenic CNV that confers risk
for ASD because may involve dosage sensitive genes essential for nor-
mal brain development. Loirat et al. (Loirat et al., 2010) reported three
patients with autism, cystic or hyperechogenic kidney carriers of
a17q12 heterozygous deletion encompassing HNF1B. Then, Nagamani
et al. (Nagamani et al., 2010) reported three cases with deletion in
17q12 presented with developmental delay/cognitive impairment. Re-
cently, two additional patients have been reported by Dixit et al. (Dixit
et al., 2012), with variable neurocognitive involvement. Very interest-
ing, rarely dysmorphic features for these patients have been document-
ed (Bernardini et al., 2009; Moreno-De Luca and SGENE Consortium,
2010). Thus, with the evidence reported to date, the 17q12 deletions
seem to be responsible for a wide range of phenotypes with consider-
able variability in expressivity and penetrance.
In this report we describe a boy with a deletion in 17q12 region de-
tected by SNP array, that showed dysmorphic features (right posterior
plagiocephaly, facial asymmetry, narrow forehead, hypotelorism, wide
and ﬂeshy auricular pavilions, protruding cheekbones, long philtrum,
thin upper lip, tuft of hair on the neck to the left parotid region,
clinodactyly of the ﬁfth ﬁngers of the hands), ID, serious speech delay
and autistic features. In addition, obesitywas observed. Clinical compar-
ison between our patient and the others previously described is report-
ed in Table 1.
The minimum size of loss was 1.428 Mbwhile the maximum size of
deletion was 1.652 Mb. Since both the proximal and the distal
breakpoints coincided with published DNA copy number polymor-
phisms and were found enriched for low-copy repeats (LCRs)
(Bellanné-Chantelot, 2005), the mechanism of the deletion was proba-
bly a non-allelic homologous recombination (NAHR) (Mefford et al.,
2009). Also, some authors reported cases carrying the reciprocal dupli-
cation of the same region (Mefford et al., 2007) providing further
evidence that these rearrangements are mediated by NAHR. The hemi-
zygous region in our patient included 16 known genes and a miRNA
and, although the 17q12 deletion genotype/phenotype correlation is
extremely variable suggesting an incomplete penetrance and variable
expressivity, haploinsufﬁciency of some of themmight explain the phe-
notype observed in our patient.
Genetic causes for autism and/or intellectual disability in patients
with 17q12 deletion are uncertain. Deletion size and breakpoint loca-
tions in our patientwith neurobehavioral phenotype, and others report-
ed with intellectual disability, are similar to those reported in patients
without these clinical features. Thus, the co-occurrence of multiple, ap-
parently unrelated, clinical ﬁndings in patients with the 17q12 deletion,
is suggestive of a contiguous gene syndrome. Under this model, major
phenotypic features may be due to haploinsufﬁciency of two or more
different genes within the deletion. HNF1B is responsible for the renal
structural abnormalities since mutations in this gene cause RCAD syn-
drome. There are no reported neurocognitive or psychiatric phenotypes
in patients with RCAD resulting from point mutations in HNF1B, al-
though this may not have been assessed in a systematic fashion. If pa-
tients with HNF1Bmutations do not show neurobehavioral phenotype,
a different gene within the deleted region may account for this compo-
nent of the phenotype. Point mutations in this other gene may also
occur in patients with a neurobehavioral impairment who do not have
the renal and endocrine phenotype due to HNF1B haploinsufﬁciency.
Of 16 genes involved in the microdeletion, in agreement with other
authors, we consider LHX1 as a serious candidate to explain the
Table 1
Clinical phenotype in patients with 17q12 deletions.
Present case Dixit et al. (2012) Nagamani et al. (2010) Moreno-De Luca and
SGENE Consortium (2010)
Loirat et al. (2010)
Age of diagnosis 12 years 12 years 4 years 7 months 5 years 4 months 13 years 18 years 9 years 4 years 3 years
Developmental delay/cognitive
impairment
+ + + NA + − + + 8/9 + + +
Seizures − − − − − + + − NA NA NA
Structural brain anomalies − − NA + − − + + NA + + NA
Dysmorphic features + − + + + − − − 8/9 NA NA NA
Renal cysts − + + + + + − + 9/9 + + +
Renal abnormalities − + + − + − − + 8/9 + + +
Obesity + − − − − − − − NA NA NA NA
Diabetes − NA NA NA NA NA NA + 1/9 NA NA NA
+, present;−, absent; NA, not available.
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scriptional regulator that plays a role in the differentiation of neural cells
and the transcriptional control of axonal guidance, it is expressed in the
brain during early development (Avrahamet al., 2009). Furthermore, an
Lhx1 knockout mouse model exhibits anencephaly, showing that LHX1
is an essential regulator of the vertebrate head organizer (Shawlot
et al., 1995). LHX1 has yet to be associated with disease in humans,
and no single gene deletions, disruptions, or mutations causing
haploinsufﬁciency have been detected. Contiguous gene disorders,
such as the 16p11.2 deletion syndrome (OMIM611913), also show con-
siderable variability (Ballif et al., 2007), with a “second hit” possibly af-
fecting severity. We sequenced LHX1 and we didn't ﬁnd any mutations
in this gene. This result strengthens our hypothesis according to which
haploinsufﬁciency of LHX1 could be the mechanism involved in the
clinical feature. Probably, being LHX1 a transcription factor strongly in-
volved in early development of central nervous system, human embryos
with a total absence of LHX1may be non-viable. We can therefore hy-
pothesize that the deletion of LHX1 is a necessary but not sufﬁcient con-
dition for arising intellectual disability. This second event could be a
smaller CNV occurring elsewhere in the genome, a small disruptivemu-
tation in a related gene, an environmental event leading to alteration in
gene dosage. Future studies are therefore necessary to identify the gene
or genes responsible for the neurobehavioral phenotype in patients
with the 17q12 deletion.
Interestingly, a non-coding RNA, miR-2909, is located within the
deleted region. Several reports indicated a role for non-coding RNAs
in the molecular pathogenesis of different developmental disorders
(Szulwach et al., 2009). We searched the miRBase database (http://
mirdb.org/miRDB/) for mRNAs containing a putative miR-2909 binding
site. This analysis revealed a large number of putative miR-2909 targets
mRNAs (Supplementary Table 2). Among these mRNAs, the highest
score was reached from FOXP2, which could explain the speech delay
and the cognitive/behavioral phenotype observed in our patient.
FOXP2 codes for a protein, expressed widely in the fetal and adult
brain, where it regulates the expression of several genes within and
among cortical, basal ganglia and cerebellar circuits (Vernes et al.,
2009). Previous studies demonstrated that FOXP2 is responsible
for speech-language disorders and cognitive impairment. To date, dis-
ruptions in FOXP2 are the only known monogenic cause of speech and
language impairment (Bacon et al., 2012; Benítez-Burraco, 2012. Fur-
thermore, it has been shown that FOXP2 directly regulates CNTNAP2,
whose mutations, like FOXP2, were found to be correlated to language
impairment (Vernes et al., 2008), and the autism candidate geneMET,
involved in neuronal differentiation (Mukamel et al., 2011). Although
we have no experimental evidence, we suppose that alterations of its
expression pattern could be causative or co-responsible for speech def-
icit and neurobehavioral features in our patient. Our hypothesis is that,
being miRNAs negative regulators of gene expression, the deletion of
one of these non-coding RNAs could cause an altered expression of tar-
get genes. This hypothesis is compatible with what is alreadydocumented in some microdeletion syndromes, for example in
22q11.2 (Xu et al., 2013) and with what has been observed in cases of
17q12 duplication, where over-expression of miR-2909 could cause
the decrease of the levels of FOXP2 expression: in fact several studies de-
scribed deletions of this gene as responsible for language and cognitive
disorders. It is widely accepted that, deletion and duplication of dose
sensitive genes, as in 22q11 deletions/duplication, may cause a similar
phenotype: mice over- and underexpressing TBX1 result in phenotypes
similar to that of velocardiofacial syndrome (VCFS) (Liao et al., 2004).
Thus we suggest that FOXP2 could be characterized by a similar mecha-
nism, and therefore speech delay and cognitive impairment observed in
our patient may be caused bymiR-2909 deletion. Obviously, to conﬁrm
this suggestive hypothesis, functional or animal studies are needed.
It is important to consider the fact that the neurological phenotype,
rather than rare, may simply be underestimated as the carriers of the
17q12 deletion are typically characterized by morphological and/or
functional alteration in the kidney and/or diabetes, and therefore
followed by specialistswho could not take into account variable expres-
sions of autistic features and intellectual disabilities. We suggest the
investigation of the presence of autistic features and intellectual disabil-
ities in a large cohort of cases–carriers of 17q12 deletion to corroborate
our hypothesis and report the incidence of these phenotypes in patients
with the deletion. Also, in our patient the parental origin of the deletion
has been investigated and it occurred in the maternal allele, thus we
cannot exclude that the phenotypic variability could also be caused by
the parental origin of the rearrangement. Therefore we suggest the in-
vestigation of the parental origin of the rearrangement, in order to con-
ﬁrm or disprove the possibility that the parental origin of the
rearrangement can somehow inﬂuence the onset of neurobehavioral
phenotype. This systematic analysis could report with more accuracy
the incidence of these phenotypes in patients with the 17q12 micro-
deletions. About the absence of the renal alterations in our patient, unlike
what emerged so far, we suggest that not only the neurobehavioral phe-
notype is subject to incomplete penetrance or variable expressivity, but
also the renal phenotype, even if this showshigher penetrance.Moreover,
although diabetes is not yet present in the patient, it is not possible to rule
out its future occurrence, while the renal phenotype typically has a very
early onset and thus should not occur at all.
Regarding the obesity reported in our patient, we focused our atten-
tion on the rule of ACACA (Acetyl-CoA carboxylase alpha) gene. Acetyl-
CoA carboxylase (ACC) is a complex multifunctional enzyme system,
which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the
rate-limiting step in fatty acid synthesis. There are two ACC forms,
alpha and beta, encoded by two different genes. ACC-alpha is highly
enriched in lipogenic tissues, and it has been reported (Jie et al., 2010)
that genes related to fatty acid synthesis, including ACACA gene, had de-
creased expression in obese rats. We sequenced ACACA gene and we
didn't ﬁnd any mutation. It is not yet clear which mechanism is in-
volved, but the deletion of this gene may be responsible for or contrib-
uted to the obesity observed in our patient. Obviously further studies
378 P. Palumbo et al. / Gene 538 (2014) 373–378are needed. This could conﬁrm the high variable expressivity that char-
acterizes this copy number variation, since this is the ﬁrst patient that
shows this feature. Also, we cannot exclude the existence of a position
effect on the genes located in the adjacent regions of the deletion as re-
ported in other genomic disorders.
In conclusion, we have described a case of a 17q12 de novo deletion,
detected by SNP array, encompassing theHNF1B gene, in a patientwith-
out renal cysts or diabetes, that shows obesity, intellectual disability, se-
rious speech delay and autistic features. Autism and ID should be
considered as manifestations associated with 17q12 microdeletions, in
particular with LHX1/mir2909 deletion, and should be investigated in
a large cohort of patients with 17q12 anomalies to conﬁrm our observa-
tions and document the exact incidence of ID in patients harboring this
deletion. Furthermore, we highlight that, differently from what has
been observed so far, renal phenotype could also be subject to incom-
plete penetrance and variable expressivity, although to a lesser extent
compared to the neurobehavioral phenotype. Our patient is also useful
to further expand the clinical spectrum of this microdeletion being the
ﬁrst one in which evident obesity has been reported and we discuss
the possible role of a candidate gene in the etiology of this trait.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2014.01.050.
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